Apr 20, 2023 8:00am EDT MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
Apr 18, 2023 8:52am EDT MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
Apr 11, 2023 8:00am EDT MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
Mar 24, 2023 4:30pm EDT MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 07, 2023 8:00am EST MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment
Feb 13, 2023 8:00am EST ADDING MULTIMEDIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition
